Home / Themes / MedTech Long '25: Centralized Lab Diagnostics
MedTech Long '25: Centralized Lab Diagnostics (view performance)
Last updated
Theme thesis · 3/5 sections · Tickers 2 with notes · 2 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsCMS premium pricing (ADLT) and broad Medicare coverage for blood-based CRC (Shield) and follow-on Cologuard 2, plus Trump-era rollback of LDT rules, are acceler
Thesis
CMS premium pricing (ADLT) and broad Medicare coverage for blood-based CRC (Shield) and follow-on Cologuard 2, plus Trump-era rollback of LDT rules, are accelerating payer uptake of ctDNA/MCED and AI-enabled pathology. EXAS, GH/GRAL, PSNL, XGN and RDNT now ride a 2025 volume inflection as health-system labs outsource high-complexity genomics and imaging-labs converge, setting the stage for double-digit top-line growth and strategic M&A.
Bull case
Shield wins CMS ADLT at $1,495 and >45 M Medicare lives, driving GH test volume CAGR > 70 %.
Exact Sciences files Cologuard 2 PMA; pilot data show 94 % sensitivity with same-day FedEx logistics, preserving centralized-lab moat.
RDNT adds 20 NGS/AI lab hubs via Aclarion partnership, funneling multimodal data to PSNL's MRD service; Personalis Q1 clinical volumes +52 % Q/Q.
Bear case
Reimbursement squeeze: GOP deficit hawks revive CLFS cuts; ADLT grace period ends, lowering Shield/Cologuard pricing.
Point-of-care shift: cheap microfluidic chips and near-patient sequencing erode centralized-lab share.
Execution risk: large-scale assays demand cap-ex; any Galleri false positives or CMS audits could chill payer adoption.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| Monthly Medicare Part B claims for Cologuard 2 (CPT 0526U) & Shield (CPT 0364U) | Monthly | Real-time adoption and payer reimbursement velocity | Google_Sheets |
| Commercial covered lives with MCED/ctDNA benefit (Shield + Galleri) | Quarterly | Breadth of reimbursement; leading indicator for volume/revenue inflection | Google_Sheets |
| Central-lab oncology test accessions processed by RadNet/PSNL (NGS + MRD) | Monthly/Quarterly | Degree of outsourcing and scaling of centralized genomic diagnostics | Google_Sheets |
Upcoming Catalysts
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| GH_551c816d | in 2026 | 2026-01-01 | 2026-12-31 | Launch of Guardant Reveal Ultra, the tumor-informed MRD/therapy monitoring test, expected to ship this year. | Could drive higher oncology volumes and strengthen Guardant360/Reveal synergy, improving growth prospects and competitive moat. | Ticker | 2026-02-19 | earnings_transcript | GH (ticker) |
| GRAL_88e14714 | in the fall | 2026-09-01 | 2026-11-30 | FDA Advisory Committee meeting for GRAIL's Galleri multi-cancer early detection test. | This meeting is a critical step in the FDA approval process for Galleri, providing external expert advice to the FDA and signaling progress towards regulatory validation. | Ticker | 2026-08-05 | earnings_transcript | GRAL (ticker) |
| GRAL_d22d5a9a | in the near future | 2026-08-10 | 2026-11-10 | Publication of detailed performance, safety, and clinical utility results from the NHS-Galleri and PATHFINDER 2 trials in top-tier journals. | Publication in top-tier journals provides further scientific validation and enhances credibility, supporting physician adoption and payer discussions for Galleri. | Ticker | 2026-08-05 | earnings_transcript | GRAL (ticker) |
| GH_707b8be0 | later this year | 2026-10-01 | 2026-12-31 | Guardant Health plans to launch Reveal Ultra, which is anticipated to be the most sensitive tumor-informed MRD test. | This new product launch is expected to redefine sensitivity in the tumor-informed MRD space, enhancing Guardant Health's competitive position and driving further volume growth in the MRD market. | Ticker | 2026-07-30 | earnings_transcript | GH (ticker) |
| GH_8850e4c8 | following ADLT designation | 2027-01-01 | 2027-06-30 | Guardant Health plans to offer widespread availability of Guardant360 Liquid CDx to U.S. customers. | This commercial rollout, following ADLT designation, will drive greater adoption of the test, simplify the therapy selection portfolio, and contribute to oncology volume growth. | Ticker | 2026-07-30 | earnings_transcript | GH (ticker) |
| GH_4fe268e1 | first half of 2027 | 2027-01-01 | 2027-06-30 | Guardant Health remains on track to obtain ADLT designation for Guardant360 Liquid CDx. | This designation is expected to lead to an immediate increase in the average selling price (ASP) for Guardant360, improving gross margins and potentially accelerating the company's timeline to cash flow breakeven. | Ticker | 2026-07-30 | earnings_transcript | GH (ticker) |
| GRAL_1d85fec4 | in the first part of 2027 | 2027-01-01 | 2027-06-30 | FDA approval of the Galleri multi-cancer early detection test following its Premarket Approval (PMA) application. | FDA approval would provide critical regulatory validation, de-risk the technology, and pave the way for broader commercialization, payer coverage, and physician adoption. | Ticker | 2026-08-05 | earnings_transcript | GRAL (ticker) |